/stocks — the workspaceLOADING
All LIMNW SEC filings, by type → · Earnings date & implied move · Search inside filings
LIMNW is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-08-14). Three months to 2026-06-30 against 2025-06-30: Net loss $1.4M, against net income of $113,287. Six months to 2026-06-30 against 2025-06-30: Operating cash used $3.0M, 66.7% smaller than $9.0M. Read it line by line, each linked to its source → · Every report →
Liminatus Pharma, Inc. (LIMNW) is a biological products, (no diagnostic substances) company. Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
No chart read for LIMNW: needs 84 sessions on file; 233 are.
What’s behind LIMNW’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has LIMNW been issuing shares? Offering history →
| Diluted EPS | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -0.43 USD | -0.20 USD | not a growth rate (a year at or below zero) | 10-K filed 2026-03-31 |
Concepts read: us-gaap:EarningsPerShareDiluted
Per filed share, as each report states it. Free cash flow per share is operating cash flow less capital expenditure, over the diluted weighted average share count (or net income over diluted EPS where the count is tagged per share class).
Each year’s change comes from one annual report, which states that year and the year before on the same share basis, and the rate compounds those changes; so a split or a restatement between reports cannot bend it. A rate needs a positive figure at both ends of its window. The DCF above grows total free cash flow and divides by today’s share count, so a per-share rate also carries the buybacks or new shares of those years. These are past figures, not a forecast.
Not shown yet: the P/E range LIMNW has traded at, which would set the discount rate and terminal assumptions against its own history. It needs a long daily price history we are not yet licensed to display.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from LIMNW’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as LIMNW tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on LIMNW plus an auto-SWOT, built from LIMNW's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate LIMNW using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about LIMNW’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from LIMNW's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentLIMNW files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
On file for LIMNW from Nov 10, 2026 to Nov 23, 2026: filing deadline (below).
| Event | Result |
|---|---|
| Earnings date | nothing in the window. No date in the window: no regular report cadence in the filings. |
| Filing deadline | on file. In the window: the 10-Q for the quarter ending Sep 30, 2026, due 40 to 45 days after it as SEC states no filer status for it, the span covers every status, falls due between Nov 9, 2026 and Nov 16, 2026. Newest periodic report on file: the 10-Q for the period ending Jun 30, 2026, filed Aug 14, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-10 to 2026-11-23, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
2 of the 2 checks that ran found nothing new for LIMNW. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
None of the 5 estimators could run on LIMNW's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for LIMNW. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for LIMNW, so sector medians could not fill the gaps.
Every refusal recorded for LIMNW → · How often we decline, and why →
Group: Biological Products, (No Diagnostic Substances), the SEC industry code LIMNW files under. 4 companies in our stored table file under it.
| Metric | LIMNW | Group median | 25th to 75th percentile | Where LIMNW sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | Withheld: 4 companies in this SIC group have the figure on file, and a group prints from 6. | |||
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | Withheld: 4 companies in this SIC group have the figure on file, and a group prints from 6. | |||
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | Withheld: 4 companies in this SIC group have the figure on file, and a group prints from 6. | |||
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Head office: Fullerton, California, United States · the company’s charter and its head office are in different states.
A charter change was filed after this. An 8-K filed 2026-08-18 reports an amendment to the company’s articles and a change to shareholder rights (Items 5.03 and 3.03). Reincorporations are reported that way, but so are routine changes such as a new series of preferred stock, and we have not read this one. If it moved the company, the next periodic report’s cover will show it.
Source: the cover page of Liminatus Pharma, Inc.’s 10-Q filed 2026-08-14, on EDGAR. Filings checked 2026-11-10. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No tracked institution reported a position in LIMNW in the latest 13F round.
No open-market Form 4 buys or sells reported for LIMNW in the last ~6 months.
No lawmaker has disclosed a trade in LIMNW under the STOCK Act.